The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm : conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Show full item record



Permalink

http://hdl.handle.net/10138/304026

Citation

Fruchart , J-C , Santos , R D , Aguilar-Salinas , C , Aikawa , M , Al Rasadi , K , Amarenco , P , Barter , P J , Ceska , R , Corsini , A , Despres , J-P , Duriez , P , Eckel , R H , Ezhov , M V , Farnier , M , Ginsberg , H N , Hermans , M P , Ishibashi , S , Karpe , F , Kodama , T , Koenig , W , Krempf , M , Lim , S , Lorenzatti , A J , McPherson , R , Millan Nunez-Cortes , J , Nordestgaard , B G , Ogawa , H , Packard , C J , Plutzky , J , Ponte-Negretti , C I , Pradhan , A , Ray , K K , Reiner , Z , Ridker , P M , Ruscica , M , Sadikot , S , Shimano , H , Sritara , P , Stock , J K , Su , T-C , Susekov , A V , Tartar , A , Taskinen , M-R , Tenenbaum , A , Tokgozoglu , L S , Tomlinson , B , Tybjaerg-Hansen , A , Valensi , P , Vrablik , M , Wahli , W , Watts , G F , Yamashita , S , Yokote , K , Zambon , A & Libby , P 2019 , ' The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm : conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation ' , Cardiovascular Diabetology , vol. 18 , 71 . https://doi.org/10.1186/s12933-019-0864-7

Title: The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm : conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
Author: Fruchart, Jean-Charles; Santos, Raul D.; Aguilar-Salinas, Carlos; Aikawa, Masanori; Al Rasadi, Khalid; Amarenco, Pierre; Barter, Philip J.; Ceska, Richard; Corsini, Alberto; Despres, Jean-Pierre; Duriez, Patrick; Eckel, Robert H.; Ezhov, Marat V.; Farnier, Michel; Ginsberg, Henry N.; Hermans, Michel P.; Ishibashi, Shun; Karpe, Fredrik; Kodama, Tatsuhiko; Koenig, Wolfgang; Krempf, Michel; Lim, Soo; Lorenzatti, Alberto J.; McPherson, Ruth; Millan Nunez-Cortes, Jesus; Nordestgaard, Borge G.; Ogawa, Hisao; Packard, Chris J.; Plutzky, Jorge; Ponte-Negretti, Carlos I.; Pradhan, Aruna; Ray, Kausik K.; Reiner, Zeljko; Ridker, Paul M.; Ruscica, Massimiliano; Sadikot, Shaukat; Shimano, Hitoshi; Sritara, Piyamitr; Stock, Jane K.; Su, Ta-Chen; Susekov, Andrey V.; Tartar, Andre; Taskinen, Marja-Riitta; Tenenbaum, Alexander; Tokgozoglu, Lale S.; Tomlinson, Brian; Tybjaerg-Hansen, Anne; Valensi, Paul; Vrablik, Michal; Wahli, Walter; Watts, Gerald F.; Yamashita, Shizuya; Yokote, Koutaro; Zambon, Alberto; Libby, Peter
Contributor: University of Helsinki, Clinicum
Date: 2019-06-04
Language: eng
Number of pages: 20
Belongs to series: Cardiovascular Diabetology
ISSN: 1475-2840
URI: http://hdl.handle.net/10138/304026
Abstract: In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARM) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARM agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARM agonist safely reduces residual cardiovascular risk.
Subject: Residual cardiovascular risk
Visceral obesity
Diabetes
Atherogenic dyslipidemia
Triglycerides
Remnant cholesterol
Selective peroxisome proliferator-activated receptor alpha modulator
SPPARMalpha
Pemafibrate (K-877)
Inflammation
PROMINENT
DENSITY-LIPOPROTEIN CHOLESTEROL
FATTY LIVER-DISEASE
ISCHEMIC-HEART-DISEASE
ALL-CAUSE MORTALITY
TRIGLYCERIDE-RICH LIPOPROTEINS
TISSUE FACTOR EXPRESSION
ACUTE-CORONARY-SYNDROME
OF-FUNCTION MUTATIONS
CARDIOVASCULAR-DISEASE
REMNANT CHOLESTEROL
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s12933_019_0864_7.pdf 1.753Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record